Four months of treatment with sitagliptin in NAFLD patients with T2DM diagnosed by ultrasonography led to significant decreased plasma glucose, HbA1c, aspertate aminotransferase (AST), and alanine transaminase (ALT) (31). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.